Business Context and Reporting Period
Company: American Vanguard Corporation (AVD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: The Company operates as a holding company primarily through its subsidiary, AMVAC Chemical Corporation, a specialty chemical manufacturer developing and marketing products for agricultural and commercial uses (insecticides, fungicides, herbicides, soil fumigants). The business is aggregated into one reportable segment. In 2010, the Company completed four significant product line acquisitions from Bayer CropScience AG and Certis-USA, expanding its portfolio in soil insecticides and fumigants.
Key Financial Metrics
| Metric (in thousands) | 2010 | 2009 |
|---|---|---|
| Net Sales | $229,620 | $209,329 |
| Gross Profit | $89,082 | $60,426 |
| Gross Margin | 38.8% | 28.9% |
| Operating Income | $19,191 | $(6,329) |
| Net Income | $10,984 | $(5,789) |
| Earnings Per Share (Diluted) | $0.40 | $(0.21) |
| Total Assets | $281,799 | $255,268 |
| Working Capital | $67,459 | $68,797 |
| Total Debt (Long-term + Current) | $62,139 | $53,960 |
| Cash Provided by Operating Activities | $33,190 | $31,951 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% to $229.6 million, driven by a 13% increase in crop sales ($204.4 million) and a 24% surge in insecticide sales. This was partially offset by a 12% decline in non-crop sales due to regulatory issues.
- Profitability Recovery: The Company returned to profitability with $11.0 million in net income, reversing a $5.8 million loss in 2009. This turnaround was significantly aided by the absence of a $13.5 million non-cash inventory write-down charge that occurred in Q4 2009.
- Margin Expansion: Gross margin improved to 39% from 29% in 2009, attributed to better plant capacity utilization, a shift to higher-margin SKUs, and the absence of the prior year's inventory charge.
- Acquisitions: The Company spent $32.7 million on product line acquisitions in 2010, adding assets such as Tebupirimfos (Aztec), Ethoprophos (Mocap), and Fenamiphos (Nemacur).
Guidance, Outlook, Risks, and Contingencies
Regulatory Risks and Contingencies
- PCNB Stop Sale Order (SSURO): In August 2010, the USEPA issued a Stop Sale, Use, and Removal Order for the Company's PCNB product line due to unlisted trace impurities. This halted domestic turf sales for the remainder of the year. The Company holds $17.4 million in inventory and $5.2 million in intangible assets related to this line. While no loss contingency has been recorded as the outcome is uncertain, a potential write-off could range up to $22.7 million if the registration is cancelled.
- Canadian PCNB Cancellation: The Pest Management Regulatory Agency (PMRA) cancelled turf uses for PCNB in Canada. The Company has accrued a $0.5 million loss contingency regarding potential inventory returns.
- DBCP Litigation: The Company faces approximately 100 lawsuits (domestic and foreign) regarding exposure to DBCP. The Company believes losses are not probable or estimable for most cases and has not accrued contingencies, citing recent court dismissals of similar cases.
Outlook and Commentary
- Seasonality: The business is cyclical and seasonal, dependent on weather patterns and crop cycles. Management notes that quarterly results may not reflect full-year performance.
- Competition: The Company faces pressure from generic competitors sourcing from low-cost countries (India, China) and competition from genetically modified (GMO) seeds which reduce pesticide usage.
- Liquidity: The Company maintains a $137 million credit facility (renewed in Jan 2011) and believes cash flows from operations are sufficient for working capital needs. As of Dec 31, 2010, the Company had capacity to borrow an additional $38.1 million under its credit facility.
Investor Verification Checklist
- PCNB Resolution: Monitor the status of the USEPA Stop Sale Order and the amended Confidential Statement of Formula (CSF) to assess the risk of a potential $22.7 million asset write-down.
- Acquisition Integration: Verify the revenue contribution and integration success of the four product lines acquired in late 2010 (Aztec, Mocap, Nemacur, Def).
- Customer Concentration: Note that three customers accounted for 55% of 2010 sales; monitor the stability of these relationships.
- Debt Covenants: Review compliance with the new credit facility covenants (funded debt ratio, fixed charge coverage, modified current ratio) effective January 2011.
- Environmental Liabilities: Track the progress of the Commerce, CA facility risk assessment and potential remediation costs, which are currently unquantified.